Jazz Pharmaceuticals PLC $JAZZ Position Lowered by Assetmark Inc.

Assetmark Inc. trimmed its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 93.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,349 shares of the specialty pharmaceutical company’s stock after selling 77,769 shares during the period. Assetmark Inc.’s holdings in Jazz Pharmaceuticals were worth $705,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Royal Bank of Canada increased its holdings in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after purchasing an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This represents a 39.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the transaction, the senior vice president owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 84,398 shares of company stock valued at $14,957,430. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JAZZ. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. JPMorgan Chase & Co. decreased their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Morgan Stanley reaffirmed an “overweight” rating and set a $225.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, January 8th. Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, November 17th. Finally, Piper Sandler restated an “overweight” rating and set a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Fourteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Trading Up 1.5%

Shares of JAZZ stock opened at $172.19 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99. The firm has a market capitalization of $10.46 billion, a PE ratio of -28.37, a price-to-earnings-growth ratio of 0.91 and a beta of 0.26. The stock has a fifty day moving average of $167.92 and a two-hundred day moving average of $148.85. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.